ALFA Finder| Revenue growth | 28.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | Consolidated EBITDA margin at 11.6%; excluding B2C, core margins at 14%. |
| Demand visibility | Strong momentum in HPPC (28%), TSC (28%), and AHN (27%) segments. |
| Management confidence | High; citing healthy momentum and robust domestic/international expansion. |
Growth
Revenue grew 28.2% YoY; EBITDA grew 18.7% YoY; PAT grew 4.5% YoY to Rs. 35.1 cr.
Outlook
New 5,000 MTPA Thailand facility commissioned; ongoing monetization of non-core assets; 15.2% FY26 revenue growth CAGR target.
Risks
Moderation in ROCE and ROE due to near-term investments; Institutional/B2C segments remained flat with negative EBITDA margins.
Last quarter's promises, checked
Delivered
- Guided 15% FY26 revenue growth → delivered 15% (= BEAT)
- Guided Q4 record revenue/EBITDA → delivered Rs 684.9 cr / Rs 77.3 cr (= BEAT)
- Guided Thailand plant commission by Q4 FY26 → delivered on stream March 2026 (= BEAT)
Partly delivered
- Guided Rs 192 cr CAPEX plan → rephased to Rs 50-75 cr for FY27 (= PARTIAL)
- Guided institutional breakeven → losses moderated but still negative (= PARTIAL)
Missed
- Guided 12-13% EBITDA margin → delivered 11.9% for FY26 (= MISS)
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹436.00
- Market cap
- ₹2,415 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.8×Sector 35.1×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.